吉非替尼在非小细胞肺癌治疗中耐药问题的研究进展  

Research progress on drug resistance of gefitinib in the treatment of non-small-cell lung cancer

作　　者：李国雁 LI Guo-yan(Department of Pharmacy,People's Hospital of Buyi and Miao Autonomous Prefecture,Qianxinan 562400,China)

机构地区：[1]黔西南布依族苗族自治州人民医院药学部,562400

出　　处：《中国现代药物应用》2024年第13期165-169,共5页Chinese Journal of Modern Drug Application

摘　　要：吉非替尼是治疗处于晚期阶段的非小细胞肺癌(NSCLC)患者的首个分子靶向药物,其主要通过对表皮生长因子受体的络氨酸激酶具有的活性进行抑制,来阻断表皮生长因子受体(EGFR)与细胞之间的信号传递通路,以此来实现对肺癌细胞的转移与异常增生的有效阻止。该药品具有副作用较少、起效速度快以及特异性相对较强的多重优势。但在药物治疗中,患者可能会需要面对耐药问题,无法实现对肺癌的彻底根治。本文首先对NSCLC的主要类型与病因进行简单介绍,而后围绕吉非替尼在NSCLC治疗中的耐药问题,从非依赖EGFR通路/旁路信号通路激活、依赖EGFR通路、组织学变化、激活EGFR下游靶标角度分析了该种耐药问题的产生机制以及应对方法,以此为出现耐药情况的NSCLC患者提供治疗思路,降低其死亡率。Gefitinib is the first molecularly targeted drug for the treatment of patients with advanced nonsmall-cell lung cancer(NSCLC),which mainly blocks the signaling pathway between epidermal growth factor receptor(EGFR)and cells by inhibiting the activity of epidermal growth factor receptor(EGFR)lysyl kinase,thus effectively preventing the metastasis and abnormal proliferation of lung cancer cells.The drug has the multiple advantages of fewer side effects,faster onset of action and relatively higher specificity.However,in drug treatment,patients may need to face the problem of drug resistance,and it is impossible to achieve a complete cure for lung cancer.This article firstly introduces the main types and causes of NSCLC,and then analyzes the resistance problem of gefitinib in the treatment of NSCLC from the perspectives of non-dependent activation of EGFR pathway/bypass signaling pathway,dependent on the EGFR pathway,histological changes,and activation of the downstream targets of EGFR,and then provides treatment ideas for NSCLC patients with drug-resistant condition.This can provide treatment ideas for NSCLC patients with drug resistance and reduce their mortality.

关 键 词：吉非替尼 非小细胞肺癌 治疗 耐药问题 

分 类 号：R734.2[医药卫生—肿瘤]